35 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Article Searches
Novartis To Initiate Hydroxychloroquine Study for Coronavirus http://www.zacks.com/stock/news/880449/novartis-to-initiate-hydroxychloroquine-study-for-coronavirus?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-880449 Apr 20, 2020 - Novartis (NVS) announces FDA's approval to evaluate hydroxychloroquine in hospitalized patients with COVID-19 in a late-stage study. The company is evaluating several of its drugs to treat COVID-19.
Optimism Back in Wall Street? ETFs Areas to Win the Most http://www.zacks.com/stock/news/875795/optimism-back-in-wall-street-etfs-areas-to-win-the-most?cid=CS-ZC-FT-etf_news_and_commentary-875795 Apr 17, 2020 - Wall Street is likely to stage a relief rally on hopes of reopening of American businesses, improving virus outlook and chances of treatment coming on stream.
Pharma Stocks Rally on Sanofi, GSK Coronavirus Vaccine Tie-Up http://www.zacks.com/stock/news/871951/pharma-stocks-rally-on-sanofi-gsk-coronavirus-vaccine-tie-up?cid=CS-ZC-FT-analyst_blog|industry_focus-871951 Apr 15, 2020 - If successful, the Sanofi (SNY) and GlaxoSmithKline plc (GSK) vaccine would be available in the second half of 2021. Shares of drugmakers jumped on the news.
Top Analyst Reports for Alibaba, Pfizer & S&P Global http://www.zacks.com/research-daily/868704/top-analyst-reports-for-alibaba-pfizer-sp-global?cid=CS-ZC-FT-research_daily-868704 Apr 13, 2020 - Top Analyst Reports for Alibaba, Pfizer & S&P Global
Forget Exxon Mobil: Here Are 3 Better Dividend Stocks https://www.fool.com/investing/2020/04/13/forget-exxon-mobil-here-are-3-better-dividend-stoc.aspx?source=iedfolrf0000001 Apr 13, 2020 - There's just too much risk in oil and gas these days.
Pfizer (PFE) Progressing Well With its Coronavirus Program http://www.zacks.com/stock/news/868613/pfizer-pfe-progressing-well-with-its-coronavirus-program?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-868613 Apr 13, 2020 - Pfizer (PFE) is developing a vaccine as well as other treatment options targeting coronavirus infection, COVID-19. However, all developments are in pre-clinical stages.
Pfizer's Braftovi Combo Gets FDA Nod for Colorectal Cancer http://www.zacks.com/stock/news/863161/pfizers-braftovi-combo-gets-fda-nod-for-colorectal-cancer?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-863161 Apr 09, 2020 - Pfizer (PFE) secures an FDA approval for Braftovi combined with Lilly's Erbitux to treat BRAFV600E-mutant metastatic colorectal cancer in patients who received prior therapy.
Is mRNA the Key to a Coronavirus Vaccine? https://www.fool.com/investing/2020/04/09/is-mrna-the-key-to-a-coronavirus-vaccine.aspx?source=iedfolrf0000001 Apr 09, 2020 - Biotech and big pharma are putting vaccines using messenger RNA to the coronavirus test.
Merck's Keytruda Gets FDA's Priority Review for Solid Tumors http://www.zacks.com/stock/news/861111/mercks-keytruda-gets-fdas-priority-review-for-solid-tumors?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-861111 Apr 08, 2020 - Merck's (MRK) sBLA seeking approval of Keytruda for advanced solid tumors, based on biomarker, regardless of tumor type, gets FDA's priority review.
Biotech Stocks, ETFs to Gain on COVID-19 Vaccine & Drug Progress http://www.zacks.com/stock/news/859545/biotech-stocks-etfs-to-gain-on-covid-19-vaccine-drug-progress?cid=CS-ZC-FT-etf_news_and_commentary-859545 Apr 07, 2020 - The race to introduce a vaccine and drug for COVID-19 is creating near-term opportunities, making the biotech sector a lucrative space for investments.

Pages: 1234

<Page 2>